Agios Reports Q4 Net Loss of $108 Million
Reports Q4 net loss $108.0M vs, net loss of $96.5M a year ago. Cash, cash equivalents and marketable securities were $1.2B at year end vs. $1.5B as of December 31, 2024. Agios expects cash, cash equivalents and marketable securities, together with anticipated product revenue and interest income, will provide the financial independence to execute the U.S. commercial launch of AQVESME in thalassemia, prepare for the potential U.S. commercial launch of mitapivat in sickle cell disease, advance the company's existing clinical programs, and expand its pipeline. "2025 was another year of continued execution across our portfolio, highlighted by the historic U.S. approval of AQVESME - the only medicine approved to treat anemia in adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. The U.S. launch is off to a strong start, with AQVESME now available and earning an enthusiastic response from the thalassemia community," said Brian Goff, CEO. "In 2026, we are focused on driving a high-impact U.S. launch of AQVESME, expanding our PK activation franchise into additional high-value indications such as sickle cell disease and lower-risk myelodysplastic syndromes, and advancing our promising early-stage pipeline to further diversify across hematologic and other rare diseases...we are very well positioned at this critical inflection point to deliver a transformative medicine for the thalassemia community and advance our clinical programs as we work toward our goal of becoming a sustainable rare disease company."
